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DNA is the molecular target for many of the drugs that
are used in cancer therapeutics. Of particular interest
are the minor groove binders, a group of DNA interac-
tive agents that bind to specific regions of the genome
and show significant toxicity towards cancer cells [1].
Alkylating agents induce permanent DNA damage and
exhibit potent antitumor activity. A range of alkylating
agents is known including monoalkylating and bifunc-
tional alkylating drugs. The latter were found to cross-
link the two complementary strands of DNA, which
usually results in more efficacious agents.
New chiral 1H,3H-pyrrolo[1,2-c]thiazoles were synthe-
sized and screened for their in vitro activity as antican-
cer agents in three human tumor cell lines, colorectal
adenocarcinoma, melanoma and breast adenocarcinoma.
(R)-6-Hydroxymethyl-5-methyl-3-phenyl-1H,3H-pyrrolo
[1,2-c]thiazole and the corresponding benzylcarbamate
showed selectivity for breast cancer cell lines with IC50
values of 2.4 μM and 2.2 μM, respectively. The latter
also showed significant activity against colorectal adeno-
carcinoma cancer cell lines (IC50 = 8.7 μM). In contrast,
the 7-hydroxymethyl-5-methyl-3-phenyl-1H,3H-pyrrolo
[1,2-c]thiazole gave moderate anticancer activity. The
performance against breast cancer cell lines (IC50 = 1.0
μM) of a potential bisalkylating agent, a (3R)-6,7-bis
(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazole, wasn’t
significantly different from the one observed for the
monoalkylanting derivatives indicating that the main
mechanism of action may in fact be the monoalkylation
process.
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